In a move that took the PACS industry by surprise, eMed Technologies announced May 17 the resignation of CEO Caren Mason. The company cited Mason’s long-distance commute from Wisconsin to eMed’s Boston-based headquarters and her
In a move that took the PACS industry by surprise, eMed Technologies announced May 17 the resignation of CEO Caren Mason. The company cited Mason’s long-distance commute from Wisconsin to eMed’s Boston-based headquarters and her responsibilities to family as reasons for her resignation. Since taking the helm in January 2000, Mason led eMed to an improved position within the PACS and networking marketplace. She also bolstered corporate finances by securing $22 million dollars in venture capital investment. The company’s board of directors has initiated a search for Mason’s replacement.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.